At present, the compound is undergoing a phase III clinical trial (NCT03254446) to assess its effectiveness in mitigating cardiovascular risk in individuals with diabetes, dyslipidemia, and hypertension [76, 77]
However, these studies suffer from methodological limitations including small sample sizes, variable berberine preparations, and heterogeneous study designs
Ask your doctor specifically why Toujeo was chosen over a GLP-1 agonist
The effect of 2.4 mg once-weekly injected semaglutide in patients with HFpEF, obesity and T2D is currently investigated in an ongoing trial STEP-HFpEF DM (Semaglutide Treatment Effect in People with obesity and HFpEF and type 2 diabetes) (64, 65)
What is the expected CAGR of the GLP-1 nutritional support market from 2025 to 2035
However, in a recent study in 106 patients with alcohol use disorder with variable degrees of liver disease, intestinal permeability normalized after a 3-week detoxification program, while markers of bacterial translocation (LBP) remained elevated (149)